AWARDDEFINITIVE CONTRACTOther than small business
Definitive contract 75F40120C00085THE UNIVERSITY OF LIVERPOOL
Overview
Award facts
- Net obligations
- $8.80M
- $8,801,123of $8.80M potential value
- Outlays (paid to date)
- $8.28M
- $8.28M paid of $8.80M obligated$8,276,639
- Period of performance
- Sep 10, 2020 to Sep 14, 2025
- Ended
- Modifications
- 5
- Latest action Sep 29, 2026
- Contract type
- Definitive contract
- PIID 75F40120C00085
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
CHARACTERIZATION OF SEVERE CORONAVIRUS INFECTION
Dates and value
- Award date
- Signed on Sep 10, 2020
- Current value
- $8,801,123Base and exercised options
- Potential value (if all options are exercised)
- $8,801,123
Obligations by fiscal year of action
- FY2026: -$611,149 (de-obligation)
- FY2022: $500,000
- FY2021: $3,510,074
- FY2020: $5,402,198
Total across 4 fiscal years: $8,801,123
Net de-obligation in that fiscal year (obligations withdrawn).
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Sep 29, 2026. View on USAspending · Recipient on SAM.gov
Recipient
LocationLIVERPOOL, MERSEYSIDE, GBR
UEIVFHSMEHGFGG5
CAGE codeU5F53
Business sizeOther than small businessSize at award, per the contracting officer
Parent companyUNIVERSITY OF LIVERPOOL
Business types and certifications
Nonprofit organizationEducational institution
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- Food And Drug Administration
- FDA OFFICE OF ACQ GRANT SVCS
- Funded by
- Department of Health and Human Services
- Food And Drug Administration
- FDA OFFICE OF ACQ GRANT SVCS
- Funded from
- Foods; Human drugs; Devices and radiological health; Fda other activities (fda headquaters); Animal drugs and feed; Biologics; Coronavirus emergency funding supplemental; Fda reimbursable program (federal sources)Program activities075-0600Federal accounts (agency financial reports)
Place of performance
- Place of performance
- United Kingdom
Classification and competition
Classification
- Product or service (PSC)
- AN91R&D- MEDICAL: OTHER (BASIC RESEARCH) (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- No set-aside used
- Contract pricing
- Firm fixed priceJ
- Offers received
- 1
Contract details
- Subcontracting plan
- Plan not included - no subcontracting possibilitiesA
- Cost Accounting Standards clause
- Not applicable exempt from CASX
- Certified cost or pricing data
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Sep 10, 2020Base obligation at award: $5,402,198
- Latest action
- Sep 29, 2026 — CloseoutModification P00005; obligation change -$611,149; administrative: no change in scope or value
- Latest substantive action
- Sep 2, 2022 — Change orderModification P00002; obligation change +$500,000
- Actions by type
- Base award1
- Other administrative action2
- Change order1
- Option exercised1
- Closeout1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- No
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
- Latest action: change in base and exercised options
- -$611,149
- Latest action: change in base and all options
- -$611,149
Socio-economic and policy
- Inherently governmental functions
- Closely associated,critical functionsCL,CT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- Other foreign entity (e.g. foreign government)O
- Country of product or service origin
- United kingdomGBR
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7524
- Contracting office code
- 75F401
- Transactions recorded under this award key
- 6
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7524
- Funding office code
- 75F401
- Treasury accounts
- 075-2020/2020-0600-000
- 075-2021/2021-0600-000
- 075-2022/2022-0600-000
- 075-X-0600-000
- Object classes
- 25.1: Advisory and assistance services
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- L: Emergency P.L. 116-123
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression
- V: Non-emergency P.L. 117-2
- COVID-19 supplemental obligations
- $4,017,136
- COVID-19 supplemental outlays
- $4,017,136